← Back to Clinical Trials
Recruiting NCT06607731
Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy
Trial Parameters
Condition Bone Angioma
Sponsor Centre Hospitalier Universitaire de Saint Etienne
Study Type OBSERVATIONAL
Phase N/A
Enrollment 11
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-06-25
Completion 2024-12
Interventions
Collecting data from medical records
Brief Summary
The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.
Eligibility Criteria
Inclusion Criteria: * Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne. Exclusion Criteria: * Patients no treated by gelled alcohol sclerotherapy.